The latest DaVita PRis an interesting read. Particularly: "Per a report by ReportLinker published on GlobeNewswire, the global end-stage renal disease market was estimated at $30.85 billion in 2020 and is expected to reach $69.92 billion by 2026 at a CAGR 14.6%. Factors like higher risk of COVID-19 exposure and infection in dialysis patients and increasing number of patients suffering from chronic kidney disease are likely to drive the market." ; - )